KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ClearPoint Neuro (CLPT) Capital Expenditures (2018 - 2025)

ClearPoint Neuro (CLPT) has disclosed Capital Expenditures for 12 consecutive years, with $49000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 81.37% to $49000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $522000.0 through Dec 2025, up 89.82% year-over-year, with the annual reading at $522000.0 for FY2025, 89.82% up from the prior year.
  • Capital Expenditures hit $49000.0 in Q4 2025 for ClearPoint Neuro, down from $199000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $323000.0 in Q2 2023 to a low of -$35000.0 in Q2 2021.
  • Historically, Capital Expenditures has averaged $107500.0 across 5 years, with a median of $72500.0 in 2022.
  • Biggest five-year swings in Capital Expenditures: crashed 94.89% in 2024 and later soared 1558.33% in 2025.
  • Year by year, Capital Expenditures stood at $38000.0 in 2021, then grew by 2.63% to $39000.0 in 2022, then crashed by 46.15% to $21000.0 in 2023, then skyrocketed by 1152.38% to $263000.0 in 2024, then plummeted by 81.37% to $49000.0 in 2025.
  • Business Quant data shows Capital Expenditures for CLPT at $49000.0 in Q4 2025, $199000.0 in Q3 2025, and $91000.0 in Q2 2025.